Energy balance
Reduction in body weight is an independent determinant of reduced intrahepatic lipid in patients with T2DM and NAFLD, regardless of the specific antidiabetic agent used.
Losing weight is the key to reducing liver fat, regardless of whether you use a GLP-1, a DPP-4 inhibitor, or lifestyle changes. The drug helps you lose weight, and the weight loss reduces the liver fat.
Multiple linear regression analysis revealed that Δweight was an independent determinant of ΔMRI–PDFF in T2DM with NAFLD (β = 0.488; 95% confidence interval, 0.046-0.930; P = 0.031)
Why this rating
Based on a secondary regression analysis within a randomized trial, providing strong statistical evidence for the correlation.
Source
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Jinhua Yan et al. · Hepatology · 2018
DOI 10.1002/hep.30320
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →